VM
VMD
VIEMED HEALTHCARE, INC.
$9.92
0.00%
$380.3M
No data for this timeframe.
Vol
Market Cap$380.3M
Cap SizeSmall Cap
Inst. Holders8 funds
Inst. Value$22.0M
Inst. Activity1 buys / 2 sells
Insider Activity0B / 3S
Insider Net $-$1.2M
SEC Reports4
Exchange Nasdaq·Sector Services-Misc Health & Allied Services, NEC·Inc. A1·CIK 0001729149·Prev Close $9.92
Recent Activity
Jun 4, 2026
SEC
Viemed Healthcare filed an 8-K reporting the results of its June 4, 2026 Annual General and Special Meeting. Shareholder
8-K — Impact 3/10
Jun 2, 2026
SEC
VieMed Healthcare filed an 8-K with an investor presentation (June 2026) highlighting record FY2025 results ($270M net r
8-K — Impact 5/10
May 5, 2026
SEC
Viemed reported Q1 2026 revenue of $75.4M (+28% YoY), beating internal trends, but GAAP diluted EPS of $0.06 missed the
8-K — Impact 5/10
Mar 20, 2026
Insider
Moore Michael sold 65,000 shares
President @ $8.77 ($570.0K)
Mar 19, 2026
Insider
Moore Michael sold 40,232 shares
President @ $9.21 ($370.5K)
Mar 18, 2026
Insider
Moore Michael sold 31,570 shares
President @ $9.42 ($297.4K)
Inst.
BANK OF AMERICA CORP — TRIM
50,291 shares ($373.7K)
Inst.
WELLS FARGO & COMPANY/MN — ADD
37,403 shares ($277.9K)
Price Targets
Historical data — last covering-analyst action Nov 2021. No current recommendation available.
$11.00 (Nov 2021)
Current $9.92
Low $11.00
Median $11.00
High $11.00
1 analysts
$11.00
$11.00
Analyst Ratings
1Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 3, 2021 | RBC Capital | MAINTAIN | Outperform |
| Mar 5, 2021 | RBC Capital | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.10 ▼ -16.7% | $0.10 — $0.10 | 25% YoY | 1 |
| Next Q | $0.13 ▲ +4.0% | $0.13 — $0.13 | 44% YoY | 1 |
| Current FY | $0.46 ▼ -5.2% | $0.44 — $0.47 | 23% YoY | 2 |
| Next FY | $0.61 ▼ -1.6% | $0.58 — $0.64 | 34% YoY | 2 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $13.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $3.3M | — |
| MORGAN STANLEY | $2.2M | ADD |
| TWO SIGMA INVESTMENTS, LP | $1.9M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $739.7K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 20, 2026 | Moore Michael | SELL | $570.0K |
| Mar 19, 2026 | Moore Michael | SELL | $370.5K |
| Mar 18, 2026 | Moore Michael | SELL | $297.4K |
| Jan 29, 2026 | Moore Michael | M | $0.00 |
| Jan 29, 2026 | Moore Michael | M | $0.00 |
8 institutional holders with $22.0M total value (2,966,216 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,782,440 | $13.2M | 60.1% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 440,800 | $3.3M | 14.9% | — |
| 3 | MORGAN STANLEY | 292,771 | $2.2M | 9.9% | ADD +67.3% |
| 4 | TWO SIGMA INVESTMENTS, LP | 261,714 | $1.9M | 8.8% | DOUBLED +193.7% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 99,562 | $739.7K | 3.4% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 50,291 | $373.7K | 1.7% | TRIM -31.3% |
| 7 | WELLS FARGO & COMPANY/MN | 37,403 | $277.9K | 1.3% | ADD +74.7% |
| 8 | FMR LLC | 1,235 | $9.2K | 0.0% | TRIM -28.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | TRIM | 73,187 | 50,291 | -31.3% | $373.7K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 21,404 | 37,403 | +74.7% | $277.9K | 2025-Q4 |
| FMR LLC | TRIM | 1,730 | 1,235 | -28.6% | $9.2K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 85,613 | 251,410 | +193.7% | $1.7M | 2025-Q3 |
| FMR LLC | ADD | 1,285 | 1,730 | +34.6% | $11.7K | 2025-Q3 |
| MORGAN STANLEY | ADD | 170,578 | 285,296 | +67.3% | $2.0M | 2025-Q2 |
| UBS Group AG | ADD | 96,285 | 189,417 | +96.7% | $1.3M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 30,395 | 94,898 | +212.2% | $655.7K | 2025-Q2 |
| FMR LLC | TRIM | 3,246 | 1,285 | -60.4% | $8.9K | 2025-Q2 |
| MORGAN STANLEY | ADD | 129,923 | 170,578 | +31.3% | $1.2M | 2025-Q1 |
| UBS Group AG | DOUBLED | 33,392 | 96,285 | +188.3% | $701.0K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 32,255 | 78,783 | +144.3% | $573.5K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 48,949 | 25,367 | -48.2% | $184.7K | 2025-Q1 |
| UBS Group AG | ADD | 17,283 | 33,392 | +93.2% | $267.8K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 10,563 | 16,024 | +51.7% | $128.5K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 269,517 | 143,963 | -46.6% | $1.1M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 99,368 | — | $728.4K | 2024-Q3 |
7 unique insiders with 3 transactions. Net insider value: -$1.2M ($0.00 bought, $1.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 20, 2026 | Moore Michael | President | SELL | 65,000 | $8.77 | $570.0K |
| Mar 19, 2026 | Moore Michael | President | SELL | 40,232 | $9.21 | $370.5K |
| Mar 18, 2026 | Moore Michael | President | SELL | 31,570 | $9.42 | $297.4K |
| Jan 29, 2026 | Moore Michael | President | M | 8,947 | $0.00 | $0.00 |
| Jan 29, 2026 | Moore Michael | President | M | 26,842 | $0.00 | $0.00 |
| Jan 29, 2026 | Moore Michael | President | D | 8,947 | $7.48 | $66.9K |
| Jan 29, 2026 | Moore Michael | President | F | 7,342 | $7.48 | $54.9K |
| Jan 29, 2026 | Moore Michael | President | M | 26,842 | $0.00 | $0.00 |
| Jan 29, 2026 | Trahan Jeremy | General Counsel | M | 3,591 | $0.00 | $0.00 |
| Jan 29, 2026 | Trahan Jeremy | General Counsel | M | 10,774 | $0.00 | $0.00 |
| Jan 29, 2026 | Trahan Jeremy | General Counsel | D | 3,591 | $7.48 | $26.9K |
| Jan 29, 2026 | Trahan Jeremy | General Counsel | F | 2,939 | $7.48 | $22.0K |
| Jan 29, 2026 | Trahan Jeremy | General Counsel | M | 10,774 | $0.00 | $0.00 |
| Jan 29, 2026 | Frazier William | Chief Medical Officer | M | 778 | $0.00 | $0.00 |
| Jan 29, 2026 | Frazier William | Chief Medical Officer | M | 2,334 | $0.00 | $0.00 |
| Jan 29, 2026 | Frazier William | Chief Medical Officer | D | 778 | $7.48 | $5.8K |
| Jan 29, 2026 | Frazier William | Chief Medical Officer | F | 802 | $7.48 | $6.0K |
| Jan 29, 2026 | Frazier William | Chief Medical Officer | M | 2,334 | $0.00 | $0.00 |
| Jan 29, 2026 | Fitzgerald Trae | Chief Financial Officer | M | 3,265 | $0.00 | $0.00 |
| Jan 29, 2026 | Fitzgerald Trae | Chief Financial Officer | M | 9,794 | $0.00 | $0.00 |
| Jan 29, 2026 | Fitzgerald Trae | Chief Financial Officer | D | 3,265 | $7.48 | $24.4K |
| Jan 29, 2026 | Fitzgerald Trae | Chief Financial Officer | F | 2,679 | $7.48 | $20.0K |
| Jan 29, 2026 | Fitzgerald Trae | Chief Financial Officer | M | 9,794 | $0.00 | $0.00 |
| Jan 29, 2026 | ZEHNDER WILLIAM TODD | Chief Operating Officer | M | 8,948 | $0.00 | $0.00 |
| Jan 29, 2026 | ZEHNDER WILLIAM TODD | Chief Operating Officer | M | 26,842 | $0.00 | $0.00 |
| Jan 29, 2026 | ZEHNDER WILLIAM TODD | Chief Operating Officer | D | 8,948 | $7.48 | $66.9K |
| Jan 29, 2026 | ZEHNDER WILLIAM TODD | Chief Operating Officer | F | 11,368 | $7.48 | $85.0K |
| Jan 29, 2026 | ZEHNDER WILLIAM TODD | Chief Operating Officer | M | 26,842 | $0.00 | $0.00 |
| Jan 29, 2026 | Hoyt Casey | Chief Executive Officer | M | 13,265 | $0.00 | $0.00 |
| Jan 29, 2026 | Hoyt Casey | Chief Executive Officer | M | 39,795 | $0.00 | $0.00 |
| Jan 29, 2026 | Hoyt Casey | Chief Executive Officer | D | 13,265 | $7.48 | $99.2K |
| Jan 29, 2026 | Hoyt Casey | Chief Executive Officer | F | 13,913 | $7.48 | $104.1K |
| Jan 29, 2026 | Hoyt Casey | Chief Executive Officer | M | 39,795 | $0.00 | $0.00 |
| Jan 29, 2026 | Cambre Jerome | Vice President of Sales | M | 2,873 | $0.00 | $0.00 |
| Jan 29, 2026 | Cambre Jerome | Vice President of Sales | M | 8,619 | $0.00 | $0.00 |
| Jan 29, 2026 | Cambre Jerome | Vice President of Sales | D | 2,873 | $7.48 | $21.5K |
| Jan 29, 2026 | Cambre Jerome | Vice President of Sales | F | 2,355 | $7.48 | $17.6K |
| Jan 29, 2026 | Cambre Jerome | Vice President of Sales | M | 8,619 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.3/10.
NEUTRAL
8-K
3/10
Viemed Healthcare filed an 8-K reporting the results of its June 4, 2026 Annual General and Special
Jun 4, 2026
NEUTRAL
8-K
5/10
VieMed Healthcare filed an 8-K with an investor presentation (June 2026) highlighting record FY2025
Jun 2, 2026
MIXED
8-K
5/10
Viemed reported Q1 2026 revenue of $75.4M (+28% YoY), beating internal trends, but GAAP diluted EPS
May 5, 2026
BULLISH
8-K
8/10
Viemed Healthcare reported record 2025 financial results with 21% revenue growth to $270.3 million a
Mar 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2021): 83% buy across 6 analysts — 1 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2021. No current recommendation available.
$11.00 mean target (Nov 2021)
$11.00 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $9.92 |
| Target Low | $11.00 |
| Target Mean | $11.00 |
| Target Median | $11.00 |
| Target High | $11.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.10 | $0.10 | $0.10 | 25.0% | -16.7% | 1↑ 1↓ | $0.1B | 23.7% | 1 |
| Next Q 2026-09-30 |
$0.13 | $0.13 | $0.13 | 44.4% | +4.0% | — | $0.1B | 12.4% | 1 |
| Current FY 2026-12-31 |
$0.46 | $0.44 | $0.47 | 23.0% | -5.2% | 0↑ 2↓ | $0.3B | 17.4% | 2 |
| Next FY 2027-12-31 |
$0.61 | $0.58 | $0.64 | 34.1% | -1.6% | — | $0.4B | 13.6% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.100 | |
| 7d ago | $0.120 | -0.020 |
| 30d ago | $0.120 | -0.020 |
| 60d ago | $0.120 | -0.020 |
| 90d ago | $0.120 | -0.020 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 3, 2021 | RBC Capital | MAINTAIN | — | Outperform |
| Mar 5, 2021 | RBC Capital | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| May 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Apr 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Mar 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Feb 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jan 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 5, 2026
earnings_calendar
VMD Q1 2026 Earnings Scheduled — 2026-05-05
Apr 13, 2026
short_interest
FTD: VMD — 62,212 shares ($0.6M) failed to deliver
Settlement: 20260413, Price: $9.51, FTD Value: $591,636.12, VIEMED HEALTHCARE IN (CANADA)
Mar 4, 2026
earnings_calendar
VMD Q4 2025 Earnings After Market Close — 2026-03-04